Anaphylm (dibutepinephrine)

Type I allergic reactions including anaphylaxis

Also known as AQST-109

Manufacturer: Aquestive Therapeutics
Regulatory submission: NDA resubmitted September 2026
Launch: Not announced
Last updated: September 21, 2026

Section

Product information and disease description Product description

Product information

109 evidence topics · 34 sources

Generic, brand name and therapeutic class of product4 evidence topics · 2 sources
Dosage forms and strengths5 evidence topics · 6 sources
Average sales price and wholesale acquisition cost7 evidence topics · 4 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 2 sources
Indication3 evidence topics · 3 sources
Pharmacology43 evidence topics · 19 sources
Contraindications/Warnings/Precautions/Adverse effects12 evidence topics · 10 sources
Special populations7 evidence topics · 5 sources
Drug/Drug, drug/disease interactions3 evidence topics · 1 source
Dosing and administration12 evidence topics · 6 sources
Access and distribution4 evidence topics · 4 sources
Co-prescribed/Concomitant therapies2 evidence topics · 2 sources
Product comparison5 evidence topics · 3 sources

Effect of dibutepinephrine on quality measures

Product-specific effect on quality measures

No evidence found.